PDCD1 and glioblastoma: Nonetheless, although only a small subset of patients (8%) profited from anti-PD1 checkpoint immuno-blockade in a recent clinical trial (NCT 02017717), responders showed an increased median overall survival compared to the standard of care, highlighting the potential of immune-targeted therapies also in treatment strategies of glioblastoma [19].